Biocon Biologics launches biosimilar ‘Hulio’ in USA

HULIO® (adalimumab-fkjp) injection, a biosimilar to Humira® (adalimumab) has been introduced in the United States after five years of experience in Europe and two years in Canada.

0
109
New Delhi: Biocon Biologics has launched HULIO® (adalimumab-fkjp) injection, a biosimilar to Humira® (adalimumab), which is now available to patients in the United States after five years of experience in Europe and two years in Canada.
Biocon Biologics, which recently announced its acquisition of Viatris’ global biosimilars business, has secured multiple biosimilar approvals in the U.S., Europe, and over 100 countries across the globe. With the acquisition of Viatris’ biosimilars business, Biocon Biologics can now help provide patients and healthcare professionals with more accessible and affordable treatment options in diabetes, cancer and immunology therapeutic areas.
“The launch of HULIO®, our biosimilar adalimumab, in the United States is an important milestone for Biocon Biologics as it expands our well-known biosimilar product offering to patients in the United States. This launch builds on our strong presence in oncology and diabetes and re-affirms our commitment to enabling affordable access to biologics,” said Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd. 
“Biocon Biologics is pleased to make HULIO®, a patient-friendly, 2-click, prefilled pen available in the United States for patients with certain inflammatory diseases. There are no buttons to push. Patients remove the cap and push the device against their skin to trigger their injection. Designed and built with patients in mind, healthcare professionals and patients don’t have to miss a beat with HULIO®; they simply, ‘Click, Click, Go,’” said Mathew Erick, Chief Commercial Officer of Advanced Markets, Biocon Biologics Ltd.